Abstract:Autologous chimeric antigen receptor T‐cell (CAR‐T) therapies have garnered unprecedented clinical success with multiple regulatory approvals for the treatment of various hematological malignancies. However, there are still several clinical challenges that limit their broad utilization for aggressive disease conditions. To address some of these challenges, allogeneic cell therapies are evaluated as an alternative approach. As compared with autologous products, they offer several advantages, such as a more standardized “off the shelf” product, reduced manufacturing complexity, and no requirement of bridging therapy. As with autologous CAR‐T therapies, allogeneic cell therapies also present clinical pharmacology challenges due to their in vivo living nature, unique pharmacokinetics or cellular kinetics (CKs), and complex dose‐exposure‐response relationships that are impacted by various patient‐ and product‐related factors. On top of that, allogeneic cell therapies present additional unique challenges, including attenuated in vivo persistence and graft‐vs.‐host disease risk as compared with autologous counterparts. This review draws comparison between autologous and allogeneic cell therapies, summarizing key engineering aspects unique to allogeneic cell therapy. Clinical pharmacology learnings from emerging clinical data of allogeneic cell therapy programs are also highlighted, with particular emphasis on CK, dose‐exposure‐response relationship, lymphodepletion regimen, repeat dosing, and patient‐ and product‐related factors that can impact CK and patient outcomes. There are specific unique challenges and opportunities arising from the development of allogeneic cell therapies, especially in optimizing lymphodepletion and establishing a regimen for repeat dosing. This review highlights how clinical pharmacologists are well positioned to help address these challenges by leveraging novel clinical pharmacology and modeling and simulation approaches.

Toward “off‐the‐shelf” allogeneic CAR T cells

Allogeneic "Off-the-Shelf" CAR T cells: Challenges and advances

‘Off-the-shelf’ allogeneic CAR T cells: development and challenges

Allogeneic CAR-T Therapy Technologies: Has the Promise Been Met?

Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks

Clinical Pharmacology Considerations for the “ Off‐the‐Shelf ” Allogeneic Cell Therapies

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

ReCARving the future: bridging CAR T-cell therapy gaps with synthetic biology, engineering, and economic insights

Strategies for Overcoming Bottlenecks in Allogeneic CAR-T Cell Therapy

Allogeneic CAR T Cells: Complex Cellular Therapy Designs Test the Limits of Our Preclinical Models

Allogeneic chimeric antigen receptor T cells for children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia

Fine-Tuning through Generations: Advances in Structure and Production of CAR-T Therapy

Off-the-shelf CAR-T cell therapies for relapsed or refractory B-cell malignancies: latest update from ASH 2023 annual meeting

Strategies to Circumvent the Side-Effects of Immunotherapy Using Allogeneic CAR-T Cells and Boost Its Efficacy: Results of Recent Clinical Trials

Use of Cell and Genome Modification Technologies to Generate Improved “Off-the-Shelf” CAR T and CAR NK Cells

Allogeneic CAR-T cells for cancer immunotherapy

Development of Stem Cell-Derived Immune Cells for Off-the-Shelf Cancer Immunotherapies

Clinical practice: chimeric antigen receptor (CAR) T cells: a major breakthrough in the battle against cancer

[Current state and future prospects of off-the-shelf allogeneic CAR NK therapy]

"Off-the-Shelf" Allogeneic CAR Cell Therapy-Neglected HvG Effect

Current Perspectives on the Use of off the Shelf CAR-T/NK Cells for the Treatment of Cancer